cancer biosimilars

Views & Analysis

Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.